EA200100826A1 - 16-галогенопроизводные эпотилона, способ их получения и их применение в фармацевтике - Google Patents

16-галогенопроизводные эпотилона, способ их получения и их применение в фармацевтике

Info

Publication number
EA200100826A1
EA200100826A1 EA200100826A EA200100826A EA200100826A1 EA 200100826 A1 EA200100826 A1 EA 200100826A1 EA 200100826 A EA200100826 A EA 200100826A EA 200100826 A EA200100826 A EA 200100826A EA 200100826 A1 EA200100826 A1 EA 200100826A1
Authority
EA
Eurasian Patent Office
Prior art keywords
epothilon
pharmaceutics
production
application
halogen derivatives
Prior art date
Application number
EA200100826A
Other languages
English (en)
Other versions
EA009206B1 (ru
Inventor
Ульрих Клар
Вернер Скубалла
Бернд Бухман
Вольфганг Шведе
Михаэль Ширнер
Original Assignee
Шеринг Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19908765A external-priority patent/DE19908765A1/de
Priority claimed from DE19954230A external-priority patent/DE19954230A1/de
Application filed by Шеринг Акциенгезельшафт filed Critical Шеринг Акциенгезельшафт
Publication of EA200100826A1 publication Critical patent/EA200100826A1/ru
Publication of EA009206B1 publication Critical patent/EA009206B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В заявке описываются новые производные эпотилона общей формулы (I)в которой Rобозначает атом галогена, прежде всего атом фтора или хлора, а остальные заместители имеют значения, указанные в описании. Новые соединения могут применяться для получения соответствующих лекарственных средств.Отчет о международном поиске был опубликован 2000.12.28.
EA200100826A 1999-02-18 2000-02-18 Производные 16-галогенэпотилона и их фармацевтическое использование EA009206B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19908765A DE19908765A1 (de) 1999-02-18 1999-02-18 16-Halogen-Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19954230A DE19954230A1 (de) 1999-11-04 1999-11-04 16-Halogen-Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
PCT/EP2000/001333 WO2000049021A2 (de) 1999-02-18 2000-02-18 16-halogen-epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung

Publications (2)

Publication Number Publication Date
EA200100826A1 true EA200100826A1 (ru) 2002-02-28
EA009206B1 EA009206B1 (ru) 2007-12-28

Family

ID=26052117

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100826A EA009206B1 (ru) 1999-02-18 2000-02-18 Производные 16-галогенэпотилона и их фармацевтическое использование

Country Status (28)

Country Link
US (3) US6610736B1 (ru)
EP (1) EP1150980B1 (ru)
JP (1) JP2002537301A (ru)
KR (1) KR100718616B1 (ru)
CN (1) CN1209360C (ru)
AR (1) AR022636A1 (ru)
AT (1) ATE370946T1 (ru)
AU (1) AU3156700A (ru)
BG (1) BG105802A (ru)
BR (1) BR0008331A (ru)
CA (1) CA2361278A1 (ru)
CZ (1) CZ20012951A3 (ru)
DE (1) DE50014587D1 (ru)
EA (1) EA009206B1 (ru)
EE (1) EE200100431A (ru)
ES (1) ES2291194T3 (ru)
HK (1) HK1044945A1 (ru)
HR (1) HRP20010677A2 (ru)
HU (1) HUP0105478A3 (ru)
IL (1) IL144519A0 (ru)
MX (1) MXPA01008328A (ru)
NO (1) NO20014013L (ru)
NZ (1) NZ513268A (ru)
PL (1) PL349863A1 (ru)
SK (1) SK11852001A3 (ru)
TW (1) TWI285645B (ru)
WO (1) WO2000049021A2 (ru)
YU (1) YU59001A (ru)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100344627C (zh) 1996-11-18 2007-10-24 生物技术研究有限公司(Gbf) 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
AU9340998A (en) * 1997-08-09 1999-03-01 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
DE10020899A1 (de) * 2000-04-20 2001-10-25 Schering Ag 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
HU229349B1 (en) 2001-01-25 2013-11-28 Bristol Myers Squibb Co Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
AU2002245296B2 (en) * 2001-01-25 2006-12-21 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
EP1353667A1 (en) 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Parenteral formulations containing epothilone analogs
EE200300397A (et) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaadid refraktaarsete kasvajate raviks
CN1774253A (zh) 2001-02-20 2006-05-17 布里斯托尔-迈尔斯斯奎布公司 用环氧丙酯酮衍生物治疗顽固性肿瘤
US7312237B2 (en) 2001-03-14 2007-12-25 Bristol-Myers Squibb Co. Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
WO2002098868A1 (en) 2001-06-01 2002-12-12 Bristol-Myers Squibb Company Epothilone derivatives
WO2003026744A1 (en) * 2001-09-25 2003-04-03 Alcon, Inc. The use of epothilones and analogs in conjunction with ophthalmic surgery
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
ES2337134T3 (es) 2002-03-12 2010-04-21 Bristol-Myers Squibb Company Derivados de c3-ciano-epotilona.
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
AU2003243561A1 (en) 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
RU2462463C2 (ru) * 2002-08-23 2012-09-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Синтез эпотилонов, их промежуточных продуктов, аналогов и их применения
PT1767535E (pt) 2002-08-23 2010-02-24 Sloan Kettering Inst Cancer Síntese de epotilonas, respectivos intermediários, análogos e suas utilizações
EP1542998A4 (en) 2002-09-23 2007-01-31 Bristol Myers Squibb Co PROCESS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILON B, AND RINSE CRYSTAL STRUCTURES OF EPOTHILON B
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
KR20070084325A (ko) * 2004-11-18 2007-08-24 브리스톨-마이어스 스큅 컴퍼니 익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
AU2006336468B2 (en) 2005-02-11 2012-04-12 University Of Southern California Method of expressing proteins with disulfide bridges
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
US20070014978A1 (en) * 2005-07-18 2007-01-18 Anthony Poloso Method of flame blocking and articles made therefrom
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
EP2065054A1 (en) * 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
WO2013092998A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of antibodies
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2685521B2 (ja) 1988-08-05 1997-12-03 株式会社日立製作所 車両用換気装置
EP0353732A3 (de) * 1988-08-05 1991-11-06 Ciba-Geigy Ag Neue Fluorolefine, Verfahren zu deren Herstellung und deren Verwendung
OA09338A (fr) * 1989-12-27 1992-09-15 Monsanto Co "Pyridines substituées".
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
AU9340998A (en) * 1997-08-09 1999-03-01 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
WO2000000485A1 (de) * 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
DE10020517A1 (de) * 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung

Also Published As

Publication number Publication date
KR100718616B1 (ko) 2007-05-16
HUP0105478A3 (en) 2002-08-28
BG105802A (bg) 2002-03-29
KR20010102215A (ko) 2001-11-15
CA2361278A1 (en) 2000-08-24
US6610736B1 (en) 2003-08-26
CN1341115A (zh) 2002-03-20
WO2000049021A3 (de) 2000-12-28
CZ20012951A3 (cs) 2001-11-14
HRP20010677A2 (en) 2005-06-30
MXPA01008328A (es) 2002-06-04
ATE370946T1 (de) 2007-09-15
YU59001A (sh) 2005-07-19
PL349863A1 (en) 2002-09-23
JP2002537301A (ja) 2002-11-05
EA009206B1 (ru) 2007-12-28
SK11852001A3 (sk) 2002-04-04
TWI285645B (en) 2007-08-21
NO20014013D0 (no) 2001-08-17
EP1150980B1 (de) 2007-08-22
HUP0105478A2 (en) 2002-06-29
EP1150980A2 (de) 2001-11-07
HK1044945A1 (en) 2002-11-08
DE50014587D1 (de) 2007-10-04
EE200100431A (et) 2002-12-16
NZ513268A (en) 2004-05-28
BR0008331A (pt) 2002-01-29
AR022636A1 (es) 2002-09-04
NO20014013L (no) 2001-10-18
US6930102B2 (en) 2005-08-16
US20040014978A1 (en) 2004-01-22
AU3156700A (en) 2000-09-04
CN1209360C (zh) 2005-07-06
ES2291194T3 (es) 2008-03-01
US20050187270A1 (en) 2005-08-25
WO2000049021A2 (de) 2000-08-24
IL144519A0 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
EA200100826A1 (ru) 16-галогенопроизводные эпотилона, способ их получения и их применение в фармацевтике
EA200200873A1 (ru) Новые пиперазиновые производные
EA200300211A1 (ru) Азабициклические соединения, способ их получения и их применение в качестве лекарственных средств, в частности в качестве антибактериальных средств
DE60140456D1 (de) Aza heterocyclische derivate und ihre therapeutische verwendung
PT863875E (pt) Novos compostos 4-(oxialcoxifenil)-3-oxi-piperidina para o tratamento de insuficiencia cardiaca e renal
EA200300674A1 (ru) Получение гетероциклических сульфонамидных ингибиторов бета-амилоида
ATE248824T1 (de) Substituierte phenylderivate, ihre herstellung und verwendung
BR9205811A (pt) Derivados heterociclicos de aminas ciclicas
EA200500600A1 (ru) Выбранные cgrp-антагонисты, способ их получения, а также их применение в качестве лекарственных средств
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200300836A1 (ru) Производные фталазинон-пиперидина в качестве ингибиторов pde4
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200500601A1 (ru) Выбранные cgrp-антагонисты, способ их получения, а также их применение в качестве лекарственных средств
EA200101133A1 (ru) Способ ингибирования агрегации амилоидных белков и визуализации амилоидных отложений с использованием производных изоиндолина
EA200400223A1 (ru) Новые производные 2h-пиридазин-3-она, фармацевтические композиции, содержащие эти производные, и способ получения активного ингредиента
EA200301276A1 (ru) Новые производные сульфоновых кислот
DK506587A (da) Imidderivater
EA200200447A1 (ru) Новые циклопропаны в качестве cgrp-антагонистов, содержащие эти соединения лекарственные средства и способ их получения
EA199900279A1 (ru) Производные бензамида и их применение в качестве лекарственных средств с лтв4-антагонистической активностью
EA200400208A1 (ru) Фенилацетамидотиазольные производные, способ их получения и их использования в качестве противоопухолевых средств
DE3882895T2 (de) Imid-Derivate, ihre Herstellung und Verwendung.
EA200400806A1 (ru) Способ получения эхинокандиновых соединений
NO873873D0 (no) Kinoxalinforbindelser samt fremgangsmaate for fremstilling derav.
BRPI0408117A (pt) compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos
FI893901A0 (fi) Menetelmä tetrasyklisten masennuslääkkeiden valmistamiseksi